

Spleen Tyrosine Kinase Inhibitor Eased RA

BY DENISE NAPOLI

FROM THE NEW ENGLAND
JOURNAL OF MEDICINE

Adding an oral, spleen tyrosine kinase inhibitor to an existing methotrexate regimen significantly lessened rheumatoid arthritis symptoms in patients with active disease, compared with placebo.

The results, though, were not without

side effects, including hypertension, neutropenia, and diarrhea.

The phase II, double-blind, placebo-controlled study was sponsored by the drug's maker, Rigel Pharmaceuticals.

Spleen tyrosine kinase (Syk) is an intracellular cytoplasmic tyrosine kinase that is present in the synovium. It is an important mediator for "immunoreceptor signaling in macrophages, neutrophils, mast cells, and B cells," the in-

vestigators noted. Syk inhibitors have previously been studied as therapeutic agents in cancers, including breast cancer and lymphoma.

The authors of the current study, led by Dr. Michael E. Weinblatt, codirector of the division of clinical rheumatology at Brigham and Women's Hospital and professor of medicine at Harvard Medical School, both in Boston, looked at 457 patients at 64 sites around the world,

specifically Bulgaria, Colombia, Mexico, Poland, Romania, and the United States (N. Engl. J. Med. 2010 [doi:10.1056/NEJMoa1000500]).

All patients met the American College of Rheumatology's 1987 criteria for rheumatoid arthritis and had had active RA for at least 6 months prior to enrolling in the trial. The 1987 ACR criteria define "active" RA as involving six swollen joints, plus six tender joints, plus either an

For patients with type 2 diabetes whose blood glucose is uncontrolled with orals alone

**THIS IS NOT JUST A TIRE
IT'S SOMETHING WE TAKE
FOR GRANTED UNTIL IT'S
WEARING OUT**



Important Safety Information for Lantus® (insulin glargine [rDNA origin] injection) (cont'd)

Warnings and Precautions (cont'd)

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Please see additional Important Safety Information for Lantus® continued on the next page.

Learn more at www.RethinkInsulin.com

elevated erythrocyte sedimentation rate or an elevated C-reactive protein level.

Patients also had been receiving a “stable dose” of methotrexate for at least 3 months (between 7.5 mg and 25 mg/wk), plus folic acid or folinic acid supplements.

Patients were randomized to four groups. The first group ($n = 152$) received the Syk inhibitor known as R788, in twice-daily doses of 100 mg. The second group ($n = 152$) received once-daily, 150-mg doses of the drug. The third group received placebo twice daily, and the fourth received once-daily placebo

(total number of placebo patients = 153).

The majority of patients in all groups were female, and the mean age was 52 years in all groups.

Overall, 67% of patients in the R788 twice-daily, 100-mg dose group registered an ACR 20 response at 6 months; in the once-daily, 150-mg group, the response rate was 57%. Both numbers were significantly higher than among placebo patients, who had a response rate of 35% (P less than .001 for both comparisons).

The authors also found that patients taking the twice-daily Syk inhibitor re-

sponded sooner than those on the once-daily regimen or placebo. By the end of the first week, 36% of twice-daily patients had an ACR 20 response, compared with 23% in the once-daily R788 group and 14% in the placebo group (P less than .001 for the twice-daily group and $P = .04$ for the once-daily group, compared with placebo).

Moreover, 31% of the twice-daily R788 group achieved remission (defined by a Disease Activity Score-28 less than 2.6) by 6 months, compared with 21% in the once-daily group and 7% in the placebo group (P less than .001 for the twice-daily

group and $P = .003$ for the once-daily group, compared with placebo).

The therapy did have adverse events. Ten patients in the once-daily group and five in the twice-daily group withdrew, mostly because of nausea and diarrhea. There were also two serious infections in the once-daily group and five in the twice-daily group, as well as neutropenia and hypertension.

Three authors, including Dr. Weinblatt, disclosed financial relationships to multiple pharmaceutical makers, including Rigel; the remaining three are employees of Rigel. ■

ADVERTISEMENT



JUST LIKE THE PANCREAS

By the time of diagnosis, patients may have lost up to 50% of β -cell function, and it may continue to decline, on average, by approximately 5% annually.¹

Patients may not know that their pancreas is no longer making enough insulin and that their disease has progressed.²

Based on data from 2003-2004, about 40% of patients with diabetes nationwide were not adequately controlled^a—and may have spent an average of 5 years with an A1C >8% from diagnosis to insulin initiation.^{3,4}

You may be surprised that in a survey, about 80% of patients with type 2 diabetes taking oral antidiabetic drugs said they would consider taking insulin based on your recommendation.⁵

Patients may focus on blaming themselves for their uncontrolled blood glucose, but you can help them focus on turning this negative mindset into positive action for managing their disease.²

Insulin may help make a difference. Insulin is an effective medication for lowering blood glucose levels. It works as part of an overall treatment plan.^b

So, consider prescribing insulin today to help lower blood glucose for your appropriate patients.

Important Safety Information for Lantus[®] (insulin glargine [rDNA origin] injection) (*cont'd*)

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Other adverse reactions commonly associated with Lantus[®] are injection site reaction, lipodystrophy, pruritus, and rash.

Please see brief summary of full prescribing information for Lantus[®] on the following pages.

^aGlucose control defined as A1C <7%.

^bIncluding diet, exercise, and other diabetes medications.

References: 1. Holman RR. *Diabetes Res Clin Pract.* 1998;40(suppl):S21-S25. 2. Polonsky WH, Jackson RA. *Clin Diabetes.* 2004;22(3):147-150. 3. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. *Diabetes Care.* 2008;31(1):81-86. 4. Brown JB, Nichols GA, Perry A. *Diabetes Care.* 2004;27(7):1535-1540. 5. Data on file, sanofi-aventis U.S. LLC.

INSULIN
IMPROVING BLOOD GLUCOSE
CONTROL SHOULDN'T WAIT